Xencor Inc 4
4 · Xencor Inc · Filed Dec 6, 2013
Insider Transaction Report
Form 4
Xencor IncXNCR
FLEMING JONATHAN
Director
Transactions
- Conversion
Common Stock
2013-12-06+17,429→ 790,881 total(indirect: By Partnership) - Conversion
Series A-1 Preferred Stock
2013-12-06−2,397,704→ 0 total(indirect: By Partnership)→ Common Stock (773,452 underlying) - Conversion
Common Stock
2013-12-06+773,452→ 773,452 total(indirect: By Partnership) - Conversion
Series A-1 Preferred Stock
2013-12-06−54,031→ 0 total(indirect: By Partnership)→ Common Stock (17,429 underlying)
Footnotes (3)
- [F1]Every 3.1 shares of the Series A-1 Preferred Stock is convertible into 1 share of the Issuer's Common Stock at any time, at the holder's election, and has no expiration date.
- [F2]These securities are owned by Oxford Bioscience Partners V, L.P. ("Oxford"). The Reporting Person is a general partner of OBP Management V L.P., which is the sole general partner of Oxford. The Reporting Person disclaims beneficial ownership in those securities in which he does not have a pecuniary interest, and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16.
- [F3]These securities are owned by mRNA Fund V, L.P. ("mRNA"). The Reporting Person is a general partner of OBP Management V L.P., which is the sole general partner of mRNA. The Reporting Person disclaims beneficial ownership in those securities in which he does not have a pecuniary interest, and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16.